Physician profile
Kirk Watson
NPI 1548398498
$5,738.37
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $861 · 2021: $1,164 · 2022: $1,213 · 2023: $1,247 · 2024: $38.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $966.35 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $866.42 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $793.80 | 2019-2023 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $604.24 | 2019-2023 | |
| Amgen INC. | $371.30 | 2019-2023 | Repatha |
| Teva Pharmaceuticals USA, INC. | $215.71 | 2019-2023 | Austedo Xr, Ajovy, Austedo |
| Astellas Pharma US INC | $172.54 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.84 | 2020-2024 | Xifaxan |
| Allergan, INC. | $154.31 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.23 | 2019-2022 | |
| Abbott Laboratories | $135.37 | 2021-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company Ltd. | $102.77 | 2022 | |
| Horizon Therapeutics Plc | $97.64 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $83.67 | 2020-2021 | |
| Lilly USA, LLC | $78.93 | 2021-2023 | Mounjaro |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.